Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in MRI of the Brain

Trial Profile

Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in MRI of the Brain

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Gadobenic acid (Primary) ; Gadoteric acid
  • Indications Brain disorders
  • Focus Diagnostic use
  • Acronyms BENEFIT
  • Sponsors Bracco Diagnostics
  • Most Recent Events

    • 14 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 26 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top